# Contents


| | | page |
|---|---|---|
| *Abstract* | | I |
| *Acknowledgements* | | iii |
| *Contents* | | v |
| *List of Figures* | | vii |
| *List of Tables* | | ix |
| *List of Symbols* | | x |
| *List of Abbreviations* | | xi |
| **Chapter 1: Introduction** | | **1-3** |
| 1.1 | Purpose of this Study | 1-2 |
| 1.2 | A Brief Outline of the Results and Future Outlook of the Present Work | 3 |
| | *1.2.1 Lanosterol Elevates Cytoprotective Response through Induced-Proteasomal Degradation of Aberrant Proteins* | 3 |
| | *1.2.2 Valproate Mediated Proteasome Dysfunctions Induce Apoptosis* | 3 |
| **Chapter 2: Review of Literature** | | **5-14** |
| 2.1 | Introduction To Cellular Proteostasis | 5 |
| 2.2 | Proteostasis in Cells During Protein Translation | 5-7 |
| 2.3 | The Components of Cellular Protein Quality Control Machinery | 7-12 |
| | *2.3.1 Molecular Chaperones* | 7-9 |
| | *2.3.2 Ubiquitin-Proteasome System* | 9-10 |
| | *2.3.3 Autophagy* | 11-12 |
| 2.4 | Impaired Protein Quality Control Machinery is Linked with Disease Conditions | 12-14 |
| | *2.4.1 Depleted and Impaired Protein Quality Control Machinery is Linked with Neurodegenerative Diseases* | 12-13 |
| | *2.4.2 The Increased Dependence on Protein Quality Control Machinery in Abnormally Proliferating Cancer Cells* | 13-14 |
| 2.5 | Protein Quality Control Machinery as Therapeutic Target | 14-15 |
| | *2.5.1 Lanosterol – An Endogenous Natural Biomolecule with Potential for Aberrant Protein Aggregate Clearance* | 14 |
| | *2.5.2 Valproate – A HDAC Inhibitor Drug with Potential for Protein Quality Control Modulation and Anti-cancer Characteristics* | 14-15 |
| **Chapter 3: Lanosterol Elevates Cytoprotective Response Through Induced-Proteasomal Degradation of Aberrant Proteins** | | **16-43** |
| 3.1 | Results | 16-40 |
| | *3.1.1 Lanosterol Treatment Increases Endogenous Levels of Proteasome and Prevents Aggregation of Model Proteins* | 16-19 |
| | *3.1.2 Treatment of Lanosterol Facilitates Proteasomal Degradation of Bona Fide Misfolded Proteins* | 19-21 |
| | *3.1.3 Lanosterol Suppresses the Accumulation of Neurotoxic Proteins* | 21-23 |
| | *3.1.4 Lanosterol Induces the Protein Quality Control Components, Including Proteasome* | 24-26 |
| | *3.1.5 In Silico Docking Analysis of Lanosterol with Proteasome Subunits* | 26-28 |
| | *3.1.6 Lanosterol Treatment Elevates Proteolytic Activities of Proteasome* | 28-30 |
| | *3.1.7 Lanosterol-mediated Proteasomal Upregulation Promotes the Degradation of Ataxin-3 Expanded Polyglutamine Proteins* | 30-32 |
| | *3.1.8 Lanosterol Promotes the Clearance of Huntington Disease Associated Proteins via Proteasomal Pathway* | 32-34 |
| | *3.1.9 Lanosterol Reduces Misfolded Proteins and Improves Cell Survival Under Stress Conditions* | 35-37 |
| | *3.1.10 Lanosterol-mediated Enhancement of Proteasome Functions Alleviates Cytotoxicity* | 38-40 |
| 3.2 | Discussion | 41-42 |
| 3.3 | Concluding Remarks | 43 |

| | | page |
|---|---|---|
| **Chapter 4: Valproate Mediated Proteasome Dysfunctions Induce Apoptosis** | | **44-70** |
| 4.1 | Results | 44-68 |
| | *4.1.1 Valproate Induces the Intracellular Accumulation of Ubiquitin Positive Inclusions* | 44-47 |
| | *4.1.2 Cellular Treatment of Valproate Promotes Aggregation of Polyglutamine Proteins by Impairing their Proteasomal Degradation* | 47-51 |
| | *4.1.3 Exposure of Cells to Valproate Generates Cytotoxic Effects Associated with Proteasome Dysfunction* | 51-54 |
| | *4.1.4 Valproate Inhibits Proteasome Catalytic Activities* | 54-56 |
| | *4.1.5 Valproate Triggered Proteasome Inhibition Induces Accumulation of Proteasome Substrates* | 56-59 |
| | *4.1.6 Accumulation of Pro-Apoptotic Proteins During Valproate-Induced Proteasome Dysfunction* | 59-61 |
| | *4.1.7 Valproate Triggered Proteasome Inhibition Leads to Mitochondrial Dysfunction and Cellular Insults* | 61-65 |
| | *4.1.8 Valproate Associated Mitochondrial Abnormalities and Apoptosis Induction* | 65-68 |
| 4.2 | Discussion | 68-70 |
| 4.3 | Concluding Remarks | 70 |
| **Chapter 5: Conclusion** | | **71-72** |
| 5.1 | Summary | 71-72 |
| 5.2 | Concluding Remarks | 72 |
| 5.3 | Closing Comments and Future Prospects | 72 |
| **Annexure A: Materials and Methods** | | **73-78** |
| A.1 | Materials | 73-74 |
| | *A.1.1 Cell Lines Used in the Study* | 74 |
| A.2 | Methods | 75-78 |
| | *A.2.1 Cell Culture, Transfection, and Drug Treatment* | 75 |
| | *A.2.2 Immunofluorescence Investigation and Aggregate Counting* | 75 |
| | *A.2.3 Proteasome Activity Assay* | 75 |
| | *A.2.4 MTT Cell Viability Assay* | 76 |
| | *A.2.5 Immunoblotting Analysis* | 76 |
| | *A.2.6 Molecular Docking* | 76 |
| | *A.2.7 Luciferase Activity Assay* | 77 |
| | *A.2.8 Cycloheximide Chase Assay* | 77 |
| | *A.2.9 Dot Blot Analysis* | 77 |
| | *A.2.10 Luciferase Reporter Gene Assay* | 77 |
| | *A.2.11 Propidium Iodide Staining* | 77 |
| | *A.2.12 DNA Fragmentation and Nucleus Architecture Analysis* | 78 |
| | *A.2.13 TUNEL Assay* | 78 |
| | *A.2.14 JC-1 Ratiometric Fluorescent Dye Staining* | 78 |
| | *A.2.15 Flow Cytometry and Statistical Analysis* | 78 |
| Bibliography | | 79 |
| *References* | | 80-93 |